Lars Jacob Stovner MD, PhD, Professor of Neurology, Norwegian University of Science and Technology and Norwegian Advisory Unit on Headaches, St. Olavs Hospital, Trondheim, Norway. 
Sweden, Denmark, Norway and Finland have independently developed their regulations for reimbursing treatment with anti-CGRP monoclonal antibodies, resulting in different levels of access to treatment and inconsistent eligibility criteria.